Beam Therapeutics Inc. (BEAM)
Automate Your Wheel Strategy on BEAM
With Tiblio's Option Bot, you can configure your own wheel strategy including BEAM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BEAM
- Rev/Share 0.7227
- Book/Share 12.7665
- PB 1.3128
- Debt/Equity 0.1408
- CurrentRatio 8.8142
- ROIC -0.3218
- MktCap 1685335320.0
- FreeCF/Share -4.1029
- PFCF -4.6691
- PE -3.8066
- Debt/Assets 0.1078
- DivYield 0
- ROE -0.4424
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BEAM | BofA Securities | Neutral | Buy | -- | $42 | March 28, 2025 |
| Upgrade | BEAM | Scotiabank | Sector Perform | Sector Outperform | -- | $40 | March 10, 2025 |
| Upgrade | BEAM | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Jan. 29, 2025 |
| Initiation | BEAM | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.
Read More
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Read More
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Read More
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
Read More
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101
Read More
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
Read More
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago.
Read More
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Presented in Second Half of 2025 Ended First Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities, …
Read More
Power Ranking Our Top Stock Picks of 2025
Published: April 01, 2025 by: Schaeffers Research
Sentiment: Positive
Subscribers to Chart of the Week received this commentary on Sunday, March 30.
Read More
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Published: March 31, 2025 by: Invezz
Sentiment: Negative
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Read More
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Read More
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Published: March 10, 2025 by: Benzinga
Sentiment: Positive
On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.
Read More
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Read More
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans …
Read More
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Read More
About Beam Therapeutics Inc. (BEAM)
- IPO Date 2020-02-06
- Website https://www.beamtx.com
- Industry Biotechnology
- CEO Mr. John M. Evans M.B.A.
- Employees 393